صفحه 1 از جانب 39 نتایج
TECHNICAL FIELD
This invention relates to a method of treating edematous retinal disorders. Specifically, this invention relates to a method of removing pathological fluid accumulation in subretinal and intra-retinal spaces. This invention also relates to dinucleoside polyphosphate salts, such as a
FIELD OF THE INVENTION
This invention relates to novel tricyclic vasopressin receptor antagonists. By interrupting the binding of the peptide hormone vasopressin to its receptors, the antagonists are useful for treating conditions involving increased vascular resistance and cardiac
This invention relates to novel tricyclic vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions involving increased vascular resistance and
FIELD OF THE INVENTION
This invention relates to novel tricyclic vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions involving increased
FIELD OF THE INVENTION
This invention is directed to certain novel [1,4]benzodiazepine compounds, their synthesis, and their use as vasopressin V2 receptor antagonists. More particularly, the compounds of the present invention interfere with the binding of the peptide hormone, vasopressin, to its
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted spirobenzazepines useful as, for example, vasopressin receptor antagonists.
BACKGROUND OF THE INVENTION
Vasopressin is a nonpeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone effects
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted spiroheterobenzazepines useful as, for example, vasopressin receptor antagonists.
BACKGROUND OF THE INVENTION
Vasopressin is a nonapeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted spiroheterobenzazepines useful as, for example, vasopressin receptor antagonists.
BACKGROUND OF THE INVENTION
Vasopressin is a nonapeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions
SEQUENCE LISTING
The instant application contains a Sequence Listing, which is entitled QUARK0005US_SeqListing.txt, created on Aug. 30, 2013 and 2280 kb in size, and is hereby incorporated by reference in its entirety.
Throughout this application various patents and publications are cited. The
SEQUENCE LISTING
The instant application contains a Sequence Listing, which is entitled 115340_22802_sequence listing 28OCT15.txt, submitted on Oct. 28, 2015 and 2,279.79 kb in size and is hereby incorporated by reference in its entirety.
Throughout this application various patents and publications